The Impact of a Negative 111Indium-Capromab Pendetide Scan Before Salvage Radiotherapy

Journal of Urology

Volumn 175, Issue 5, 2006, Pages 1668-1672

  Proaño, Juan M ^a   Sodee, D Bruce ^a   Resnick, Martin I ^a   Einstein, Douglas B ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

capromab pendetide; local; neoplasm recurrence; prostate; prostatic neoplasms; radiotherapy

Indexed keywords

CAPROMAB PENDETIDE IN 111; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CHEMICAL ANALYSIS; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; FOLLOW UP; HORMONAL THERAPY; HUMAN; MALE; PELVIS; PELVIS LYMPH NODE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SALVAGE THERAPY; SEMINAL VESICLE; STATISTICAL ANALYSIS;

AGED; ANTIBODIES, MONOCLONAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 33645979654     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00982-1     Document Type: Article

References (20)

1. Moul J.W. Prostate specific antigen only progression of prostate cancer. J Urol 163 (2000) 1632
2. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591
3. Stephenson A.J., Shariat S.F., Zelfsky M.J., Kattan M.W., Butler E.B., Teh B.S., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325
4. Leventis A.K., Sharait S.F., Kattan M.W., Butler E.B., Wheeler T.M., and Slawin K.M. Prediction of response to salvage radiotherapy in patients with prostate cancer recurrence of radical prostatectomy. J Clin Oncol 19 (2001) 1030
5. Thomas C.T., Bradshaw P.T., Pollock B.H., Montie J.E., Taylor J.M., Thames H.D., et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 21 (2003) 1715
6. Lange P.H. ProstaScint scan for staging prostate cancer. Urology 57 (2001) 402
7. Wilkinson S., and Chodak G. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. J Urol 172 (2004) 133
8. Kahn D., Williams R.D., Haseman M.K., Reed N.L., Miller S.J., and Gerstbrein J. Radioimmunoscintigraphy with In 111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 16 (1998) 284
9. Sodee D.B., Faulhaber P.F., and Devlin M.S. Prostascint/CT fusion improvement of accuracy as compared to planar/SPECT imaging. analysis of 49 prostate cancer patients (2005), Presented at annual conference of Academy of Molecular Imaging, Orlando, Florida March 18-23
10. Schettino C.J., Kramer E.L., Noz M.E., Taneja S., Padmanabhan P., and Lepor H. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. AJR Am J Roentgenol 183 (2004) 519
11. Sodee D.B., Nelson A.D., Faulhaber P.F., Maclennan G.T., Resnick M.I., and Bakale G. Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer 3 (2005) 230
12. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement. guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035
13. Raj G.V., Partin A.W., and Polascik T.J. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 94 (2002) 987
14. Israeli R.S., Powell C.T., Corr J.G., Fair W.R., and Heston W.D. Expression of prostate-specific membrane antigen. Cancer Res 54 (1994) 1807
15. Bostwick D.G., Pacelli A., Blute M., Roche P., and Murphy G.P. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma. a study of 184 cases. Cancer 82 (1998) 2256
16. Kahn D.J., Austin C., Miller S., and Williams R.D. In-111 capromab pendetide mab scan predicts response to radiotherapy to the prostate fossa in men with tumor recurrence following radical prostatectomy. 3 year follow-up. J Urol 161 suppl. (1999) S239
17. Ellis R.J., Kim Y.E., Conant R., Sodee D.B., Spirnack J.P., Dinchman K.H., et al. Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. Int J Radiat Oncol Biol Phys 49 (2001) 1281
18. Manyak M.J., Hinkle G.H., Olsen J.O., Chiaccherini R.P., Partin A.W., Piantadosi S., et al. Immunoscintigraphy with indium-111-capromab pendetide. evaluation before definitive therapy in patients with prostate cancer. Urology 54 (1999) 1058
19. Rosenthal S.A., Haseman M.K., and Polascik T.J. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol 7 (2001) 27
20. 177lutetium-labeled J591, a monoclonal antibody to prostate specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23 (2005) 4591